These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12737333)

  • 41. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.
    Clegg DO; Reda DJ; Abdellatif M
    Arthritis Rheum; 1999 Nov; 42(11):2325-9. PubMed ID: 10555027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?
    Braun J; Sieper J
    Ann Rheum Dis; 2000 Jun; 59(6):404-7. PubMed ID: 10834852
    [No Abstract]   [Full Text] [Related]  

  • 44. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
    Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2013; 31(3):365-71. PubMed ID: 23294554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment.
    Zou JX; Braun J; Sieper J
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S34-7. PubMed ID: 12463444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Filippatos TD; Vasakos S; Nikas SN; Drosos AA
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L; Kruithof E; Van Damme N; Hoffman IE; Van den Bossche N; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of reactive arthritis.
    Palazzi C; Olivieri I; D'Amico E; Pennese E; Petricca A
    Expert Opin Pharmacother; 2004 Jan; 5(1):61-70. PubMed ID: 14680436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment resistant ankylosing spondylitis with peripheral joint involvement - a case for infliximab?
    Hrycaj P; Lacki JK
    J Rheumatol; 2003 Jan; 30(1):204-6; author reply 206. PubMed ID: 12508417
    [No Abstract]   [Full Text] [Related]  

  • 51. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis.
    Meador R; Hsia E; Kitumnuaypong T; Schumacher HR
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S130-4. PubMed ID: 12463463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2005 Feb; 64(2):229-34. PubMed ID: 15388511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset.
    Maria Lizzio M; Peluso G; Zoli A; Gremese E; Tolusso B; Ferraccioli G
    Ann Rheum Dis; 2007 Mar; 66(3):427-8. PubMed ID: 17311903
    [No Abstract]   [Full Text] [Related]  

  • 54. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
    Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of infliximab treatment on QT intervals in patients with ankylosing spondylitis.
    Senel S; Cobankara V; Taskoylu O; Guclu A; Evrengul H; Kaya MG
    J Investig Med; 2011 Dec; 59(8):1273-5. PubMed ID: 21955979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment outcome of spondyloarthropathy with infliximab].
    Głowska A; Wiland P; Szechiński J
    Pol Arch Med Wewn; 2005 Jan; 113(1):42-7. PubMed ID: 16130600
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Vasakos S; Nikas SN; Drosos AA
    Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis.
    Cornec D; Devauchelle Pensec V; Joulin SJ; Saraux A
    Arthritis Rheum; 2009 Jun; 60(6):1657-60. PubMed ID: 19479855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders.
    Agirbasli M; Inanc N; Baykan OA; Direskeneli H
    Clin Exp Rheumatol; 2006; 24(5):580-3. PubMed ID: 17181930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.